Lead Product(s): Cell-penetrating peptides conjugates
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Peptide
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $45.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing December 09, 2020
PepGen will use the funding to advance into the clinic their next-generation cell-penetrating peptides conjugated to phosphorodiamidate morpholino oligomers (PPMOs) that are designed to correct genetic defects in diseases with high unmet medical need.